Fig. 2From: Clinical decisions surrounding genomic and proteomic testing among United States veterans treated for lung cancer within the Veterans Health AdministrationEGFR and proteomic test results and use of erlotinib. This diagram does not include the timing of testing and drug prescriptionBack to article page